Published • loading... • Updated
Boston Scientific Cuts 2026 Guidance for Third Time This Year
The company lowered revenue growth to 4.25% and adjusted earnings per share to $3.16 to $3.18 after a cyberattack and weaker Watchman sales.
Summary by MedTech Dive
7 Articles
7 Articles
Boston Scientific warns of tough 2027 on China pricing, heart-device weakness
By Padmanabhan Ananthan Oct 28 (Reuters) – Boston Scientific lowered its full-year profit forecast on Wednesday and warned that revenue and earnings growth could be challenging in 2027, citing pricing pressure in China and weakness in its key heart-device businesses. Shares of the company were down 5.3% by afternoon. “We anticipate continued top-line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earn…
(Teleborsa) - Boston Scientific recorded net sales of 5,138 billion dollars in the third quarter of 2026, with an increase of 1.5% on a declared, operational and organic basis compared to...
Coverage Details
Total News Sources7
Leaning Left0Leaning Right2Center2Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
